Our proteomic data suggested the disturbance of processes related to cell movement, highlighted by decreased levels of several proteins involved in glioma migration, such as CD9 [23] and EPHB3 [42] after treatment with Gos or ATO/Gos, as well as EPHA2 after treatment with GANT/Gos. Here, CD9 is linked to central nervous system cancer.